CERC Cerecor Inc.

2.57
+0.15  (+6%)
Previous Close 2.42
Open 2.33
Price To Book 7.56
Market Cap 160,412,705
Shares 62,417,395
Volume 107,780
Short Ratio
Av. Daily Volume 123,482
Stock charts supplied by TradingView

NewsSee all news

  1. Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome

    ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan

  2. Cerecor Reports 2019 Results

    -Company Transformed Into Orphan and Rare Disease Biotech-Clear Corporate Strategy with New Leadership-Significant Advancement in Pipeline and Regulatory Milestones ROCKVILLE, Md., March 11, 2020 (GLOBE NEWSWIRE) --

  3. Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer

    ROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan

  4. Cerecor and Aevi Genomic Medicine Complete Merger

    -Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020

  5. Cerecor to Acquire Aevi Genomic Medicine

    -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer-Strategic Alternatives

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b initial data due 2H 2020.
CERC-002 (AEVI-002)
Pediatric onset Crohn's disease
Phase 2 top-line data released December 5, 2016 - endpoint not met.
CERC-501
Smoking cessation
Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.
CERC-301
Major depressive disorder (MDD)
Phase 1 commencement of enrolment announced November 11, 2019.
CERC-301
Diabetic Orthostatic Hypotension
NDA planned 2021.
CERC 801
Phosphoglucomutase 1 (PGM1) deficiency
Phase 1 initial data due 1H 2020.
CERC-802
Healthy volunteers
Phase 1b/2 data due 4Q 2020 / 1Q 2021.
CERC-007
Adult Onset Still's Disease (AOSD) and Multiple Myeloma (MM)
Phase 1/2 data due 1H 2021.
CERC-006
Lymphatic Malformations

Latest News

  1. Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome

    ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan

  2. Cerecor Reports 2019 Results

    -Company Transformed Into Orphan and Rare Disease Biotech-Clear Corporate Strategy with New Leadership-Significant Advancement in Pipeline and Regulatory Milestones ROCKVILLE, Md., March 11, 2020 (GLOBE NEWSWIRE) --

  3. Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer

    ROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan

  4. Cerecor and Aevi Genomic Medicine Complete Merger

    -Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020

  5. Cerecor to Acquire Aevi Genomic Medicine

    -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer-Strategic Alternatives

  6. Cerecor to Acquire Aevi Genomic Medicine

    PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. ("Aevi") (NASDAQ:GNMX) today announced that it entered into a definitive merger agreement with Cerecor, Inc. ("Cerecor")

  7. Cerecor Reports Third Quarter 2019 Results

    Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 MillionFirst Patient Enrolled in Diabetic OH Trial with CERC-301Completed Phase 1 Healthy Volunteer Study with CERC-802CERC-802 IND Accepted by FDA and

  8. Cerecor Announces Clinical Updates on CERC-301 and CERC-802

    - CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc.

  9. Aytu BioScience Announces Hiring of Matthew Phillips as Executive Vice President of Commercial Operations

    ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today

  10. Cerecor Closes Deal to Sell Pediatric Portfolio

    ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and

  11. Cerecor To Sell Pediatric Portfolio to AYTU BioScience

    -Deal Valued in Excess of $32 Million-Eliminates Debt Associated with Avadel / Deerfield Agreement-Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Submission of CERC-801 ROCKVILLE,